Do we need to consider inflammatory markers when we treat atherosclerotic disease?

被引：84

作者：

Athyros, Vasilios G. ^{[1
]}

Kakafika, Anna I. ^{[1
]}

Karagiannis, Asterios ^{[1
]}

Mikhailidis, Dimitri P. ^{[2
]}

机构：

[1] Aristotle Univ Thessaloniki, Hippocration Hosp, Sch Med, Propedeut Dept Internal Med 2, Thessaloniki, Greece

[2] Univ London, Univ Coll London, Royal Free Univ Coll Med Sch, Royal Free Hosp,Dept Clin Biochem,Vasc Prevent Cl, London, England

来源：

ATHEROSCLEROSIS | 2008年 / 200卷 / 01期

关键词：

cardiovascular disease; non-alcoholic fatty liver disease; autoimmune disease; inflammation; C-reactive protein; statins; angiotensin II blockade;

D O I：

10.1016/j.atherosclerosis.2008.02.026

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This review considers the value of monitoring inflammatory markers as a guide to selecting appropriate drugs in patients at high risk of cardiovascular disease (CVD). Clinical and experimental studies investigated inflammation in patients with acute coronary syndromes (ACS), stable coronary artery disease (CAD) and diabetes mellitus (DM) or metabolic syndrome (MetS), non-alcoholic fatty liver disease (NAFLD) or systemic autoimmune diseases (SAD). Evidence suggests that in these high risk groups inflammation plays a role in the extent and severity of atherosclerosis. Simple inflammatory markers (e.g. C-reactive protein and fibrinogen) can be monitored cost effectively and may influence the selection of drugs that can normalize both traditional CVD risk factors and inflammation. However, this concept requires proof in appropriately designed trials that include clinically relevant end points. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 12

页数：12

共 82 条

[1] Inflammation: A pivotal link between autoimmune diseases and atherosclerosis [J].

Abou-Raya, Anna ;

Abou-Raya, Suzan .

AUTOIMMUNITY REVIEWS, 2006, 5 (05) :331-337

[2] Task force 1: The ACCF and AHA codes of conduct in human subjects research [J].

Adams, RJ ;

Antman, EM ;

Kavey, REW .

CIRCULATION, 2004, 110 (16) :2512-2516

[3]

Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365

[4] Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome - A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study [J].

Athyros, Vasilios G. ;

Mikhailidis, Dimitri P. ;

Liberopoulos, Evangelos N. ;

Kakafika, Anna I. ;

Karagiannis, Asterios ;

Papageorgiou, Athanasios A. ;

Tziomalos, Konstantinos ;

Ganotakis, Emmanuel S. ;

Elisaf, Moses .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (01) :118-127

[5] Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study [J].

Athyros, Vasilios G. ;

Mikhailidis, Dimitri P. ;

Didangelos, Triandafillos P. ;

Giouleme, Olga I. ;

Liberopoulos, Evangelos N. ;

Karagiannis, Asterios ;

Kakafika, Anna I. ;

Tziomalos, Konstantinos ;

Burroughs, Andrew K. ;

Elisaf, Moses S. .

CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) :873-883

[6] Targeting vascular risk in patients with metabolic syndrome but without diabetes [J].

Athyros, VG ;

Mikhailidis, DP ;

Papageorgiou, AA ;

Didangelos, TP ;

Peletidou, A ;

Kleta, D ;

Karagiannis, A ;

Kakafika, AI ;

Tziomalos, K ;

Elisaf, M .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (08) :1065-1074

[7] Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METSGREECE Multicentre Study [J].

Athyros, VG ;

Mikhailidis, DP ;

Papageorgiou, AA ;

Didangelos, TP ;

Ganotakis, ES ;

Symeonidis, AN ;

Daskalopoulou, SS ;

Kakafika, AI ;

Elisaf, M .

CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (11) :1691-1701

[8] Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus - A subgroup analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study [J].

Athyros, VG ;

Papageorgiou, AA ;

Symeonidis, AN ;

Didangelos, TP ;

Pehlivanidis, AN ;

Bouloukos, VI ;

Mikhailidis, DP .

ANGIOLOGY, 2003, 54 (06) :679-690

[9] Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease [J].

Athyros, VG ;

Mikhailidis, DP ;

Papageorgiou, AA ;

Bouloukos, VI ;

Pehlivanidis, AN ;

Symeonidis, AN ;

Elisaf, M .

JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (11) :781-788

[10] Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in Type 2 diabetic men with or without coronary heart disease? [J].

Bahceci, M ;

Tuzcu, A ;

Ogun, C ;

Canoruc, N ;

Iltimur, K ;

Aslan, C .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (02) :145-150

← 1 2 3 4 5 6 7 8 9 →